No Data
No Data
Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH): Received drug clinical trial approval letter for new indication of Venetoclax.
On July 8th, Gelunhui reports that Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH) announced that the company recently received the "Drug Clinical Trial Approval Notice" issued and approved by the National Medical Products Administration. The clinical study of the new indication for sulfonic acid fumeitinib tablets (referred to as "fumeitinib") obtained drug clinical trial approval. Fumeitinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), which is a type 1 small molecule targeted drug independently developed by the company. Fumeitinib belongs to a highly selective and irreversible third-generation EGFR-TKI, mainly used in the treatment of EGFR mutation non-small cell lung cancer, with the potential to cross the blood-brain barrier.
HKEX Live | WuXi Biologics and Shanghai Allist Pharmaceuticals Co., Ltd. collaborate to conduct clinical research on combination therapy for advanced non-small cell lung cancer, and How Yu-B (02256) surges more than 8% in the afternoon.
Wah Yuet Group B (02256) rose more than 8% in the afternoon. As of press time, it has risen 7.14% to HKD 3.45 with a turnover of HKD 3.1682 million.
With EPS Growth And More, Shanghai Allist Pharmaceuticals (SHSE:688578) Makes An Interesting Case
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage
Alice (688578.SH) 2023 equity distribution: $0.40 per share, share registration on May 30
According to Zhitong Finance App News, Alice (688578.SH) issued the 2023 equity distribution implementation notice. The profit distribution is based on the company's total share capital before implementation of the plan, with a cash dividend of 0.40 yuan (tax included) per share. The share registration date is May 30, 2024, and the exclusion (interest) date is May 31, 2024.
Shanghai Allist Pharmaceuticals Co., Ltd.'s (SHSE:688578) Top Owners Are Private Companies With 44% Stake, While 28% Is Held by Individual Investors
Key Insights Shanghai Allist Pharmaceuticals' significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public 51% of the business is hel
Abbisko Cayman Unit's Cancer Drug To Be Clinically Tested in Combination With Shanghai Allist's Furmonertinib
Abbisko Cayman (HKG:2256) unit Abbisko Therapeutics said its investigational non-small cell lung cancer drug ABSK043 would be clinically tested in combination with Furmonertinib Mesilate Tablets, acco
No Data